BioArctic AB’s partner Eisai announced that “LEQEMBI® Intravenous Infusion” has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease.
BioArctic AB’s partner Eisai announced that “LEQEMBI® Intravenous Infusion” has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease.